CAS 877399-52-5

Crizotinib

Descripción:

Crizotinib es un inhibidor de la tirosina quinasa de pequeñas moléculas utilizado principalmente en el tratamiento de ciertos tipos de cáncer de pulmón de células no pequeñas (CPCNP) que presentan mutaciones genéticas específicas, como reordenamientos de ALK (quinasa de linfoma anaplásico) y alteraciones del gen ROS1. Su fórmula química es C21H22Cl2N4O2, y presenta una estructura compleja que incluye un núcleo bicíclico. Crizotinib actúa inhibiendo selectivamente la actividad de las quinasas ALK y ROS1, interrumpiendo así las vías de señalización que promueven el crecimiento y la supervivencia del tumor. La sustancia se administra típicamente por vía oral y es conocida por su capacidad para penetrar la barrera hematoencefálica, lo que la hace efectiva contra las metástasis cerebrales. Los efectos secundarios comunes pueden incluir náuseas, diarrea y alteraciones visuales. Debido a su mecanismo de acción dirigido, Crizotinib representa un avance significativo en la terapia personalizada contra el cáncer, permitiendo opciones de tratamiento más efectivas basadas en el perfil molecular del tumor. Como con cualquier medicamento, su uso debe ser guiado por un profesional de la salud, considerando posibles interacciones y contraindicaciones.

Fórmula: C₂₁H₂₂Cl₂FN₅O

InChI: InChI=1/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

Clave InChI: InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N

SMILES: O([C@H](C)C1=C(Cl)C(F)=CC=C1Cl)C2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N

Sinónimos:

• (5-(Pyridin-3-Yl)-1,3,4-Oxadiazol-2-Yl)Methanamine
• (R)-3-[1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-ylamine
• 2-Pyridinamine, 3-[(1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy]-5-[1-(4-Piperidinyl)-1H-Pyrazol-4-Yl]-
• 3-((R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
• 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine
• 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
• Crizotinib
• Pf 2341066
• Pf-02341066
• Pf2341066
• Xalkori
• [3-[[(R)-1-(2,6-Dichloro-3-fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]amine
• 3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
• (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
• [3-[[(R)-1-(2,6-Dichloro-3-
• 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine
• PF-2341066/Crizotinib
• k-ras(g12c) inhibitor 6 NA
• fluorophenyl)ethyl]oxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-yl]aMine
• Crozotinib
• 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]-2-aMinopyridine
• Crizotinib (PF2341066)
• PF-02341066 Crizotinib

3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine

CAS: 877399-52-5

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: 98%

Forma y color: Solid

Peso molecular: 450.3367

Ref: IN-DA0036BC

(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine

CAS: 877399-52-5

(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: 95%

Forma y color: Solid

Peso molecular: 450.33668

Ref: 54-PC402134

Crizotinib

CAS: 877399-52-5

Fórmula: C₂₁H₂₂Cl₂FN₅O

Forma y color: White To Off-White Solid

Peso molecular: 450.34

Ref: 4Z-C-123001

Crizotinib

CAS: 877399-52-5

Crizotinib

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: ≥98%

Peso molecular: 450.34

Ref: 54-BUP15747

Crizotinib

CAS: 877399-52-5

Forma y color: Neat

Ref: 86-MM3930.00

Crizotinib (Standard)

CAS: 877399-52-5

Crizotinib (Standard) is a reference standard for research and analysis in studies involving Crizotinib. Crizotinib (PF-02341066) is a small molecule tyrosine kinase inhibitor that inhibits c-MET and ALK receptors (IC50=8/20 nM), is ATP-competitive, and also inhibits ROS1. Crizotinib exhibits antitumor activity and inhibits tumor growth.

Fórmula: C₂₁H₂₂Cl₂FN₅O

Forma y color: Solid

Peso molecular: 450.34

Ref: TM-TMSM-3371

Crizotinib

CAS: 877399-52-5

Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: 99% - 99.87%

Forma y color: White Solid

Peso molecular: 450.34

Ref: TM-T1661

Crizotinib

CAS: 877399-52-5

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: ≥ 98.0%

Forma y color: White to off-white powder

Peso molecular: 450.34

Ref: 7W-GW2561

Crizotinib

CAS: 877399-52-5

(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: 98%

Peso molecular: 450.34

Ref: IN-DG161410

Crizotinib

CAS: 877399-52-5

Pureza: 95%

Forma y color: Solid

Peso molecular: 450.339996337891

Ref: 10-F793129

Crizotinib

CAS: 877399-52-5

Inhibits receptor tyrosine kinases c-MET and ALK; antineoplastic

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: Min. 98 Area-%

Forma y color: Powder

Peso molecular: 450.34 g/mol

Ref: 3D-FD20585

Crizotinib - Bio-X ™

CAS: 877399-52-5

Crizotinib is a drug that belongs to the group of tyrosine kinase inhibitors. It is used in the treatment of cancers, including non-small cell lung cancer, small cell lung cancer, and other types of solid tumours. Crizotinib inhibits the activity of the tyrosine kinase ALK or anaplastic lymphoma kinase, which is involved in many signalling pathways and biological processes. The inhibition of this enzyme leads to decreased energy metabolism, reduced mitochondrial membrane potential and increased susceptibility to apoptosis.

Fórmula: C₂₁H₂₂Cl₂FN₅O

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 450.34 g/mol

Ref: 3D-BC164334

Crizotinib

CAS: 877399-52-5

Fórmula: C₂₁H₂₂Cl₂FN₅O

Peso molecular: 450.34

Ref: ST-EA-CP-C101000